NO20110577L - Mutasjon av parkingen, preparater, fremgangsmater og anvendelser - Google Patents

Mutasjon av parkingen, preparater, fremgangsmater og anvendelser

Info

Publication number
NO20110577L
NO20110577L NO20110577A NO20110577A NO20110577L NO 20110577 L NO20110577 L NO 20110577L NO 20110577 A NO20110577 A NO 20110577A NO 20110577 A NO20110577 A NO 20110577A NO 20110577 L NO20110577 L NO 20110577L
Authority
NO
Norway
Prior art keywords
gene
parkin
exons
deletion
amplifying
Prior art date
Application number
NO20110577A
Other languages
English (en)
Other versions
NO332174B1 (no
Inventor
Alexis Brice
Cristophe Lucking
Nacer Eddine Abbas
Patrice Denefle
Sylvain Ricard
Sandrine Bouley
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9814524A external-priority patent/FR2786199B1/fr
Priority claimed from FR9910140A external-priority patent/FR2797272B1/fr
Publication of NO20110577L publication Critical patent/NO20110577L/no
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO332174B1 publication Critical patent/NO332174B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20110577A 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse NO332174B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9814524A FR2786199B1 (fr) 1998-11-19 1998-11-19 Mutations du gene de la parkine, compositions, methodes et utilisations
US12423999P 1999-03-12 1999-03-12
FR9910140A FR2797272B1 (fr) 1999-08-04 1999-08-04 Nouvelles mutations du gene de la parkine, compositions, methodes et utilisations
PCT/FR1999/002833 WO2000031253A2 (fr) 1998-11-19 1999-11-18 Mutations du gene de la parkine, compositions, methodes et utilisations

Publications (2)

Publication Number Publication Date
NO20110577L true NO20110577L (no) 2001-07-18
NO332174B1 NO332174B1 (no) 2012-07-16

Family

ID=27253486

Family Applications (5)

Application Number Title Priority Date Filing Date
NO20012342A NO330896B1 (no) 1998-11-19 2001-05-11 Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser.
NO20110578A NO332173B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse.
NO20110582A NO333907B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse.
NO20110577A NO332174B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse
NO20110580A NO333906B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO20012342A NO330896B1 (no) 1998-11-19 2001-05-11 Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser.
NO20110578A NO332173B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse.
NO20110582A NO333907B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20110580A NO333906B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse

Country Status (15)

Country Link
US (3) US8835618B2 (no)
EP (5) EP2345722A1 (no)
JP (1) JP5424519B2 (no)
AT (1) ATE440138T1 (no)
AU (1) AU778281B2 (no)
CA (1) CA2351567C (no)
CY (1) CY1110535T1 (no)
DE (1) DE69941300D1 (no)
DK (1) DK1131424T3 (no)
ES (1) ES2330281T3 (no)
IL (3) IL142755A0 (no)
NO (5) NO330896B1 (no)
NZ (1) NZ512313A (no)
PT (1) PT1131424E (no)
WO (1) WO2000031253A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1081225A1 (en) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenic animal model for neurodegenerative diseases
AU2001264950A1 (en) * 2000-05-26 2001-12-11 Duke University Methods of screening for parkinson's disease
FR2845245A1 (fr) * 2002-10-07 2004-04-09 Aventis Pharma Sa Modele animal de la maladie de parkinson
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
CN110295147A (zh) * 2019-07-22 2019-10-01 新乡医学院 一种食管癌细胞系中功能基因敲除后增殖表型的快速鉴定方法及其应用
JP2023526449A (ja) * 2020-05-21 2023-06-21 ニスノバイオ ジーティー，エルエルシー パーキンソン病を治療するための、増加した活性を有するパーキン変異体の遺伝子治療送達

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009914A1 (en) * 1993-10-05 1995-04-13 Asahi Glass Company Ltd. Multicloning vector, expression vector, and production of foreign protein with expression vector
ES2168472T3 (es) 1995-06-06 2002-06-16 Beth Israel Hospital Procedimiento y aparato para ensayo diagnostico de adn.
ES2257029T3 (es) 1998-02-09 2006-07-16 Boehringer Ingelheim International Gmbh Dnas o genes que participan en la enfermedad de parkinson.
CA2872581C (fr) * 1998-11-19 2018-04-10 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations

Also Published As

Publication number Publication date
NO20012342L (no) 2001-07-18
JP2002536961A (ja) 2002-11-05
AU1276900A (en) 2000-06-13
DK1131424T3 (da) 2009-11-23
AU778281B2 (en) 2004-11-25
WO2000031253A2 (fr) 2000-06-02
NO20110580L (no) 2001-07-18
EP2128257A2 (fr) 2009-12-02
US8835618B2 (en) 2014-09-16
NO332174B1 (no) 2012-07-16
US9540693B2 (en) 2017-01-10
EP2128257A3 (fr) 2010-03-03
US20170183736A1 (en) 2017-06-29
EP2305816A1 (fr) 2011-04-06
JP5424519B2 (ja) 2014-02-26
EP2311954A1 (fr) 2011-04-20
EP1131424B1 (fr) 2009-08-19
US20150074836A1 (en) 2015-03-12
NO20110578L (no) 2001-07-18
NO330896B1 (no) 2011-08-08
CA2351567C (fr) 2016-01-12
PT1131424E (pt) 2009-10-23
NO20012342D0 (no) 2001-05-11
IL142755A (en) 2009-08-03
NO333906B1 (no) 2013-10-14
WO2000031253A3 (fr) 2000-09-28
DE69941300D1 (de) 2009-10-01
NZ512313A (en) 2003-12-19
EP2345722A1 (fr) 2011-07-20
EP1131424A2 (fr) 2001-09-12
NO20110582L (no) 2001-07-18
CA2351567A1 (fr) 2000-06-02
ATE440138T1 (de) 2009-09-15
IL142755A0 (en) 2002-03-10
US20120064598A1 (en) 2012-03-15
CY1110535T1 (el) 2015-04-29
ES2330281T3 (es) 2009-12-07
NO333907B1 (no) 2013-10-14
IL187652A (en) 2010-02-17
NO332173B1 (no) 2012-07-16

Similar Documents

Publication Publication Date Title
NO20110578L (no) Mutasjon av parkingen, preparater, fremgangsmater og anvendelser
Manchenko Handbook of detection of enzymes on electrophoretic gels
Ying et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome
GB2376018A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human placenta
Ordway et al. Cysteine 64 of Ref-1 is not essential for redox regulation of AP-1 DNA binding
ATE391175T1 (de) Multidrug resistenz gen
Nakano et al. Variants in pancreatic carboxypeptidase genes CPA2 and CPB1 are not associated with chronic pancreatitis
JP2003517830A5 (no)
EP0274482A4 (en) Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells.
Owerbach et al. Inheritance of a parotid secretory protein in mice and its use in determining salivary amylase quantitative variants
Matsubara et al. Mammalian 5-formyluracil− DNA glycosylase. 1. Identification and characterization of a novel activity that releases 5-formyluracil from DNA
Cao et al. Association of matrix metalloproteinase‐1 promoter polymorphism with generalized aggressive periodontitis in a Chinese population
Su et al. Two novel mutations in the gene encoding thyroxine‐binding globulin (TBG) as a cause of complete TBG deficiency in Taiwan
ATE373095T1 (de) Mutierte muskelspezifische enhancer
DE60023691D1 (de) T-bet zusammensetzungen und deren vervendungsmethoden
ATE315104T1 (de) Glaukom diagnose und behandlung
WO2002086113A3 (en) Enzyme and snp marker for disease
Hashemipour et al. Thyroid peroxidase gene mutation in patients with congenital hypothyroidism in Isfahan, Iran
CN101240325A (zh) 一种检测遗传基因修复能力的试剂盒
Henry Differentiation of allozyme loci to distinguish between two species of Eisenia
Christensen et al. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin
Budden et al. S. pombe Rtf2 is Important for Replication Fork Barrier Activity of RTS1 via Splicing of Rtf1
Harris Mutagenicity of chemicals and drugs
Cortopassi Molecular genetics and evolution of P lysozyme
Lyons et al. Prospects for Comparative Genome Analyses Among Mammals

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees